Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Sabari on the Role of Concurrent Molecular Testing in Lung Cancer

January 27th 2021

Joshua K. Sabari, MD, discusses the role of concurrent plasma- and tissue-based molecular testing in lung cancer.

Sabari Stresses the Importance of Molecular Testing in Lung Cancer

January 27th 2021

Joshua K. Sabari, MD, discussed the management of patients with early-stage and metastatic lung cancer, the roles of molecular testing, surgery, staging, and ongoing research efforts in the space.

Dr. Rizvi on the Implications of the CheckMate-227 Trial With Nivolumab/Ipilimumab in NSCLC

January 26th 2021

Naiyer A. Rizvi, MD, discusses the clinical implications of the CheckMate-227 trial examining the use of nivolumab plus ipilimumab in the treatment of patients with non–small cell lung cancer.

Dr. Ohri on the Role of Chemoradiation in Locally Advanced NSCLC

January 26th 2021

Nitin Ohri, MD, discusses the role of chemoradiation therapy in locally advanced non–small cell lung cancer.

Novartis Signs In-Licensing Agreement With BeiGene to Expand Tislelizumab Trials Globally

January 26th 2021

January 26, 2021 - Novartis has signed a strategic collaboration agreement to in-license the PD-1 inhibitor tislelizumab from BeiGene, Ltd, in various markets outside of China.

Novel Checkpoints Could Broaden the Benefit of Immunotherapy in NSCLC

January 26th 2021

Martin E. Gutierrez, MD, discusses some of the most encouraging ongoing clinical trials in metastatic NSCLC.

Assessing the Advantages of Adjuvant Targeted Therapy in Lung Cancer

January 25th 2021

David Spigel, MD, discusses the future of adjuvant targeted therapy in lung cancer.

Big Data Tool Finds Variations in Treatment and Costs Across 3 Cancer Types

January 25th 2021

Using real-world data from more than 4000 patients with common cancers, an algorithm was able to detect variations in care that, if reduced, could result in a median savings of $26,773 per patient.

Durvalumab, Osimertinib Envelop Adjuvant and Neoadjuvant NSCLC Treatment

January 25th 2021

The sustained overall survival benefit with durvalumab and significant disease-free survival benefit benefit with osimertinib in the adjuvant setting represent major advances in the field of non–small cell lung cancer, fueling research with each modality in localized settings.

Lung-Sparing Nodule Resection Gains Traction in Lung Cancer, But Needs Multidisciplinary Considerations

January 24th 2021

Henning Gaissert, MD, discusses the importance of tailoring surgical resection strategies to individual patients with lung cancer.

Immunotherapy Could Restore the Value of Neoadjuvant Therapy in Lung Cancer

January 22nd 2021

David Spigel, MD, discusses ongoing research with immunotherapy in early-stage lung cancer.

Dr. Halmos on the Emergence of KRAS-Targeted Therapies in Lung Cancer

January 21st 2021

Balazs Halmos, MD, MS, discusses the emergence of KRAS-targeted therapies in lung cancer.

Forecasting Future Advances Across Oncology

January 21st 2021

Expert discuss their expectations for research and drug development in oncology in the new year.

HER2-Directed Antibody-Drug Conjugates May Carve Out a Place in NSCLC Landscape

January 21st 2021

The current standard of care for patients with non–small cell lung cancer does not include therapies targeting HER2, a mutation that occurs in up to 4% of cases. However, data from recent studies of antibody-drug conjugates directed at HER2 activity are generating excitement about the potential utility of ADCs in this space.

New Designations and Efficacy Demonstrations Push the EGFR+ NSCLC Paradigm Forward

January 20th 2021

Timothy F. Burns, MD, PhD, dissects the role of osimertinib in EGFR-mutant NSCLC, sheds light on remaining questions in the field, and speaks to some of the most intriguing emerging agents in the space.

Emerging Strategies Seek to Build on Radiation Benefits in Lung Cancer

January 19th 2021

Katie Keane, MD, highlights the evolving role of stereotactic body radiation therapy in the treatment of patients with stage I lung cancer, the utilization of immunotherapy with chemoradiation in stage III disease, and research evaluating radiation in those with oligometastatic disease.

Expert Sees Need for Better Guideline Adherence in NSCLC

January 19th 2021

At the beginning of his career as a medical oncologist in the 1990s, lung cancer specialist Rogerio C. Lilenbaum, MD, was squarely focused on diagnosing and treating his patients while translating emerging clinical research into practice.

Embracing the Charm of Uncertainty in Lung Cancer Research

January 18th 2021

Tony S.K. Mok, MD's, early research tackled a grab bag of topics, including pancreatic, colon, and lung cancers, as he tried to catch up with his colleagues.

Dr. Stiles on Treatment Advances Made in Early-Stage Lung Cancer

January 18th 2021

Brendon Stiles, MD, discusses the roles of surgery, radiation, and chemotherapy in treatment for early-stage lung cancer.

Dr. Rohs on the Role of Molecular Testing in Lung Cancer Management

January 18th 2021

Nicholas C. Rohs, MD, discusses the role of molecular testing in patients with lung cancer.